Navigation Links
Northwest Biotherapeutics Appoints Pharma Industry Veteran As CEO Of German Subsidiary

BETHESDA, Md., Sept. 18, 2012 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that it has appointed former pharmaceutical industry executive Dr. Gunter Rosskamp as the CEO of the Company's German subsidiary, Northwest Biotherapeutics, Gmbh. 


Dr. Rosskamp brings extensive experience as a senior manager in the pharmaceutical sector.  He previously served as Head of Central Nervous System (CNS) therapeutics at Schering AG (now part of Bayer AG) with responsibility for research and development, and global marketing and sales, of CNS products.  This included such drugs as Dopergin (for Parkinson's disease) and Noctamide (a sleeping aid).

Dr. Rosskamp also served as Project Leader for the development and registration (product approval) of the blockbuster drug, Betaseron (for multiple sclerosis), in the European Union.

He subsequently served as Head of Strategic Business Development at Schering AG reporting directly to the Board and determining suitable opportunities in existing franchise areas of the Company, such as hormone products and diagnostics, and new franchise areas such CNS therapeutics and cardiology. 

Dr. Rosskamp also served as Vice President of Life Sciences and Chemicals at the German Industrial Investment Council (IIC).  In that role, he developed a broad network throughout the global pharmaceutical and life sciences industry, including in the US and Asia as well as in Europe.

Dr. Rosskamp served as CEO of three biotech companies, including a company developing treatments for inflammatory and immune disorders, and two companies developing cell therapy products.  Dr. Rosskamp's experience with clinical trials and regulatory requirements for such cellular products will be particularly useful for NW Bio.

"NW Bio's DCVax technology is one of the most exciting technologies I have seen in my career," commented Dr. Rosskamp, "and NW Bio has made impressive progress in their lead program for brain cancer in both the US and Europe, and in building a deep pipeline of additional applications and product lines.  I am very pleased to join NW Bio and help with the ongoing clinical development, and the registration and commercialization of their DCVax products."    

"We are excited to have Dr. Rosskamp, a widely respected industry veteran, join our Team," commented Linda Powers, CEO of NW Bio.  "Dr. Rosskamp's wealth of experience with physicians, regulators and industry throughout the German and European pharma and biotech sectors, will provide a strategic advantage in building NW Bio's operations in Europe." 

Dr. Rosskamp succeeds Dr. Bernhard Faber, who served as the interim start-up CEO of NW Bio's German subsidiary, and who also manages the Bioville, Gmbh consulting firm.  "We appreciate Dr. Faber's helpful role in the initial establishment and launch of our German subsidiary," said Linda Powers.  "Dr. Faber made an important contribution to our German program."

For further information about the Company and its programs, please visit the Company's website at

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe.  The Company has a broad platform technology for DCVax® dendritic cell-based vaccines.  The Company's lead program is a 300-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal brain cancer.  The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I/II trials in multiple other cancers.  The Company has also conducted a Phase I/II trial with DCVax® for metastatic ovarian cancer. 


Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax® and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

SOURCE Northwest Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Northwest Bio Receives Regulatory Approval To Proceed With Its Phase III Trial In The UK
2. Northwestern University Joins VIVO Network with Elseviers SciVal Experts
3. Chicago Celebrates First Informatics Week, Co-Chaired by Intelligent Medical Objects and Northwestern University
4. Northwest Bio and Fraunhofer IZI Announce Milestones Reached
5. Northwest Bio Reaffirms Its Freedom to Operate; Refutes Other Parties Misleading Patent Assertions
6. Northwest Bio Implements Major Balance Sheet Clean-Up
7. BioSpace Spotlights Northwests Life Science Community
8. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
9. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
10. Healthpoint Biotherapeutics to Present at 30th Annual J.P. Morgan Healthcare Conference
11. Aushon BioSystems Appoints Martin Verhoef Chief Executive Officer
Post Your Comments:
(Date:11/25/2015)... IN (PRWEB) , ... November 25, 2015 , ... ... (AMA) and the Organization of Black Aerospace Professionals (OPBAP) has been formalized with ... and other AMA team leaders met with OPBAP leaders Capt. Karl Minter and ...
(Date:11/25/2015)... The Global Genomics Industry ... and in-depth study on the current state of ... ) , The report provides ... classifications, applications and industry chain structure. The Genomics ... including development trends, competitive landscape analysis, and key ...
(Date:11/24/2015)... 24, 2015  Asia-Pacific (APAC) holds the third-largest ... market. The trend of outsourcing to low-cost locations ... higher volume share for the region in the ... margins in the CRO industry will improve. ... ( ), finds that the market earned ...
(Date:11/24/2015)... 2015 Cepheid (NASDAQ: CPHD ) today ... following conference, and invited investors to participate via webcast. ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ... New York, NY      Tuesday, December 1, 2015 ...
Breaking Biology Technology:
(Date:10/29/2015)... Oct. 29, 2015 Daon, a global leader ... has released a new version of its IdentityX ... North America have already installed IdentityX ... includes a FIDO UAF certified server component ... to activate FIDO features. These customers include some of ...
(Date:10/29/2015)... 29, 2015 Today, LifeBEAM , ... with 2XU, a global leader in technical performance ... hat with advanced bio-sensing technology. The hat will ... monitor key biometrics to improve overall training performance. ... two companies will bring together the most advanced technology, ...
(Date:10/26/2015)... , October 26, 2015 /PRNewswire/ ... --> adds Biometrics ... to 2021 as well as Emerging ... research reports to its collection of ... . --> ...
Breaking Biology News(10 mins):